How can we integrate the biology of breast cancer cell dormancy into clinical practice?
Cancer Cell · 2024-07 · 42 (7) · 1147-1151
DOI: 10.1016/j.ccell.2024.05.023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2024-07. Verfasst von Islam E Elkholi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital,…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: NCI NIH HHS, US Department of Defense, National Cancer Institute.
Abstract (Originalsprache)
Clinical practice and clinical research heavily rely on primary tumors, circulating tumor DNA, and/or overt metastases as sources of material for predicting or investigating breast cancer metastatic relapses. However, these approaches do not consider emerging fundamentals in the biology of metastatic dormancy and relapse. Conversely, the field of metastatic dormancy often discounts key clinical factors influencing relapse dynamics (e.g., patient's age and overall health condition). Here, we delineate these disparities into four gaps and propose a framework to bridge them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada; Montreal Clinical Research Institute (IRCM), Mo…
- Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada.
- Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA; Cancer Dormancy and Tumor Microenvironment Institute, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine…
- Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada; Molecular Biology Programs, Université de Montréal, Montreal, QC, Canada; Department of Biochemistry and Molecular Medicine, Université de Montréal, Mon…
Förderung
- NCI NIH HHS
- US Department of Defense
- National Cancer Institute
- National Institutes of Health
- Canada Research Chairs Program
- Cancer Research Society
- Fonds de Recherche du Québec - Santé
- The Mark Foundation for Cancer Research
Zitieren
APA
Elkholi, I. E., Rose, A. A. N., Aguirre-Ghiso, J. A., & Côté, J. F. (2024). How can we integrate the biology of breast cancer cell dormancy into clinical practice?. Cancer Cell, 42(7), 1147-1151. https://doi.org/10.1016/j.ccell.2024.05.023
Vancouver
Elkholi IE, Rose AAN, Aguirre-Ghiso JA, Côté JF. How can we integrate the biology of breast cancer cell dormancy into clinical practice?. Cancer Cell. 2024;42(7):1147-1151. doi:10.1016/j.ccell.2024.05.023
BibTeX
@article{Elkholi2024,
author = {Elkholi, Islam E and Rose, April A N and Aguirre-Ghiso, Julio A and Côté, Jean-François},
title = {How can we integrate the biology of breast cancer cell dormancy into clinical practice?},
journal = {Cancer Cell},
year = {2024},
volume = {42},
number = {7},
pages = {1147--1151},
doi = {10.1016/j.ccell.2024.05.023}
}
EUVIMED